Study of the Performance of the KeyPath MRSA/MSSA Blood Culture Test - BTA

Stopped early

Conditions studied: Bacteremia

In brief

In vitro identification of S. aureus,methicillin-sensitive S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA)from positive blood culture using MicroPhage's bacteriophage-based diagnostic platform.

Key facts

Study ID

NCT01640886

Run by

MicroPhage, Inc.

People needed

764

Starts

2012-06-01

Expected to finish

2012-12-01

Last updated by the study team

2013-01-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Blood culture samples determined to be Gram-positive from subjects aged 18+, inclusive, with any of the following bottle types:
• bioMerieux BacT/ALERT® Standard Aerobic and Anaerobic
• bioMerieux BacT/ALERT® FAN Aerobic and FAN Anaerobic
• Completion of the KeyPathTM BTA Test on the sample.
• Completion of the reference method for S. aureus identification (tube coagulase and Remel Staphaurex ) and completion of the reference method for methicillin resistance determination (30 µg cefoxitin disc diffusion) for S. aureus positive samples.

You may not qualify if…

• Samples from blood culture positives over 24 hours from alarm
• Samples deemed contaminated.
• Violations and/or deviations from the KeyPathTM BTA Test protocol and/or other included test protocols under study.

Where it is running

• University of Arizona, Infectious Disease Research — Tuscon, Arizona, United States
• UCLA Clinical Laboratory — Los Angeles, California, United States
• Medical University of South Carolina — Charleston, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.